Each capsule contains Glucosamine sulfate sodium chloride equivalent to Glucosamine sulfate 500 mg.
Each capsule contains sodium 50.4 mg.
Each sachet contains Glucosamine Sulfate Sodium Chloride 1,884 mg equivalent to Glucosamine sulfate 1,500 mg.
Pharmacology: Pharmacodynamics: Capsule: Glucosamine sulfate is capable of stimulating proteoglycans synthesis and decreasing activity of catabolic enzyme such as Matrix Metalloproteinases (MMP) resulting in delay the deterioration of chondrocyte.
Sachet: Glucosamine sulfate is capable of stimulating proteoglycan synthesis, inhibiting the degradation of proteoglycans, and stimulating the regeneration of experimentally-induced cartilage damage.
Some experts also believe glucosamine sulfate might promote the incorporation of sulfur into cartilage.
Pharmacokinetics: Capsule: About 90% of Glucosamine sulfate is absorbed from small intestine. The drug is extensively metabolized by first-pass metabolism in the liver which result in low bioavailability (26%). At present, there is no information on the amount of the drug distributed to the joint.
The elimination half-life is 2.1 hours. Most of the drug is eliminated through urine and small amount of glucosamine or its derivatives eliminated in the feces.
Sachet: In humans, about 90 percent of glucosamine, administered as an oral dose of glucosamine sulfate, is absorbed from the digestive tract. After an oral dose, glucosamine concentrations in the liver, where it is either incorporated into plasma proteins, degrade into smaller molecules, or utilized for other biosynthetic process. Elimination of glucosamine is primarily though urine, with a small amount of glucosamine or its derivatives eliminated in the feces.
Relief symptoms of primary osteoarthritis.
Capsule: Adult: oral 1 capsule three times daily or 3 capsules once daily for least 6 consecutive weeks.
Sachet: The content of one sachet dissolved in water taken once daily for at least 6 weeks.
Capsule: Overdosage of glucosamine can cause any of the usual glucosamine side effects, particularly digestive upset.
Treatment: Gastric lavage or an emetic-induced medication may be given in order to get rid of glucosamine inside the stomach.
Symptomatic and supportive treatment may be required.
Sachet: Insufficient reliable information.
Capsule: Patient with seafood allergy such as shrimp, crab or iodine.
Sachet: Patients with shellfish allergy should avoid this product.
Capsule: Use with cautions in patients with diabetes, asthma, hypertension, peptic ulcer or kidney function impairment.
Prolonged use of this drug require monitoring of blood sugar and lipid levels periodically.
Sodium is a component of this drug. Use with caution in patients who need to restrict sodium intake such as heart failure or kidney disease etc.
Sachet: Diabetic patients: Initiating glucosamine therapy should be aware of the possibility of an effect on glucose levels.
Use in Pregnancy: Avoid using glucosamine in pregnant women or women who intend to have children. Should not be used because the safety information is not enough.
Sachet: Insufficient reliable information to advise on safety in pregnancy.
Use in Lactation: Should not be used because the safety information is not enough.
The most common side effects such as nausea, stomach upset, abdominal discomfort, constipation, diarrhea, drowsiness, headache, rash and skin reaction. To decrease these effects, dividing doses with meals may help the patients. One report has documented exacerbation of previously well-controlled asthma, which resolved completely upon discontinuation of a product.
Glucosamine may increase blood glucose levels and insulin resistance when using long-term treatment so diabetic patients initiating glucosamine therapy should be aware of the possibility of an effect on glucose levels, but use is not contraindicated. There are case reports of cholesterol elevations in patients using glucosamine. Lipid monitoring is recommended. The side effects that have been infrequently reported are vertigo, peripheral edema and tachycardia, blood pressure fluctuation, depression and musculoskeletal pain.
Oral administration of glucosamine at very large doses (5,000-15,000 mg/kg body weight) is well tolerated without documented toxicity. The most common symptoms reported with placebo and oral glucosamine are: mild gastrointestinal symptoms including constipation, diarrhea, nausea, dyspepsia, excessive gas, abdominal distension and abdominal cramps. Headache and skin rash or pruritus are known to occur.
This drug may reduce the effectiveness of antidiabetic drugs. Dosage adjustment of antidiabetic may be necessary.
This drug may increase anticoagulant or antiplatelet effect. Bleeding tendency may occur in these who use this drug concurrently.
This drug may reduce the effectiveness of Etoposide and Doxorubicin.
This drug may increase the risk of adverse effect of diuretics drug.
Keep in well-closed container below 30°C.
M01AX05 - glucosamine ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.
Cap 500 mg (maroon-white capsule, marked "COPH" on the maroon cap and "500 on the white body with black ink, filled with white to yellowish-white powder) x 3 x 10's. Powd for oral soln 1,500 mg (sachet, white to yellowish white powder) x 30's.